Soligenix PE Ratio 2010-2022 | SNGX

Current and historical p/e ratio for Soligenix (SNGX) from 2010 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Soligenix PE ratio as of May 27, 2022 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Soligenix PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2022-05-27 0.60 0.00
2022-03-31 0.73 $-0.25 0.00
2021-12-31 0.66 $-0.31 0.00
2021-09-30 1.06 $-0.39 0.00
2021-06-30 1.11 $-0.36 0.00
2021-03-31 1.53 $-0.41 0.00
2020-12-31 1.28 $-0.67 0.00
2020-09-30 1.79 $-0.62 0.00
2020-06-30 2.11 $-0.70 0.00
2020-03-31 1.68 $-0.72 0.00
2019-12-31 1.45 $-0.49 0.00
2019-09-30 0.95 $-0.53 0.00
2019-06-30 0.71 $-0.50 0.00
2019-03-31 0.92 $-0.56 0.00
2018-12-31 0.86 $-0.74 0.00
2018-09-30 1.88 $-0.56 0.00
2018-06-30 0.97 $-0.62 0.00
2018-03-31 1.95 $-0.85 0.00
2017-12-31 2.22 $-0.90 0.00
2017-09-30 2.23 $-1.04 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.026B $0.001B
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases where, as well as developing several biodefense vaccines and therapeutics. The Company operates in two reportable segments: BioTherapeutics and BioDefense. The BioTherapeutics business segment intends to develop orBec ? (oral beclomethasone dipropionate, or oral BDP) and other biotherapeutic products, including LPM TM Leuprolide. The BioDefense business segment intends to convert its ricin toxin vaccine and radiation injury programs from early stage development to advanced development and manufacturing. Soligenix, Inc, formerly known as DOR BioPharma, Inc, is headquartered in Princeton, New Jersey.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00